Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

17.99
+0.11500.64%
Volume:280.42K
Turnover:5.07M
Market Cap:3.32B
PE:-11.10
High:18.80
Open:18.18
Low:17.89
Close:17.87
52wk High:45.30
52wk Low:16.24
Shares:184.69M
Float Shares:81.38M
Volume Ratio:1.25
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6200
EPS(LYR):-1.6200
ROE:-29.06%
ROA:-5.01%
PB:3.31
PE(LYR):-11.10

Loading ...

Legend Biotech Q4 revenue slightly misses; expects operating profit in 2026

Reuters
·
Mar 10

Earnings Flash (LEGN) Legend Biotech Posts Q4 Loss $0.08 a Share, vs. FactSet Est of $0.02 EPS

MT Newswires Live
·
Mar 10

Legend Biotech Q4 Adj. EPS $0.01 Beats $(0.11) Estimate, Sales $306.300M Miss $306.875M Estimate.

Benzinga
·
Mar 10

BRIEF-Legend Biotech Corporation Q4 EPS USD -0.08

Reuters
·
Mar 10

Legend Biotech Corporation Q4 Revenue USD 306.3 Million VS. Ibes Estimate USD 306.9 Million

THOMSON REUTERS
·
Mar 10

Legend Biotech Corporation Q4 Pretax Profit USD -19.7 Million

THOMSON REUTERS
·
Mar 10

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

GlobeNewswire
·
Mar 10

U.S. Earnings Preview: Before Market Open March 10

Dow Jones
·
Mar 10

Legend Biotech (LEGN) Receives a Buy from Barclays

TIPRANKS
·
Mar 10

Legend Biotech Corp expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
Mar 06

Oppenheimer Reaffirms Their Buy Rating on Legend Biotech (LEGN)

TIPRANKS
·
Mar 06

Earning Preview: Legend Biotech Q1 revenue is expected to increase by 71.50%, and institutional views are cautiously optimistic

Earnings Agent
·
Mar 03

Legend Biotech Corporation to Host Investor Conference Call on Fourth-Quarter and Full-Year 2025 Results

Reuters
·
Feb 24

Legend Biotech: Undervalued BCMA CAR-T Leader with Lower Commercial Risk and DCF-Supported Upside to $50 Target

TIPRANKS
·
Feb 24

Legend Biotech rises 16.6%

TIPRANKS
·
Feb 23

Legend Biotech Shares Lower After Rothschild & Co Redburn Downgrade

MT Newswires Live
·
Feb 13

Rothschild & Co Redburn Downgrades Legend Biotech to Neutral From Buy

MT Newswires Live
·
Feb 12

Legend Biotech Names Veteran Finance Executive Gareth Kung to Board and Audit Chair Role

TIPRANKS
·
Feb 07

Legend Biotech beruft Gareth Kung in den Vorstand

Reuters
·
Feb 07

Legend Biotech Is Maintained at Overweight by Barclays

Dow Jones
·
Feb 04